Omega Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Omega Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50,000	Closed	-$4.68M	–	95
2017 Q2	$4.68M	Buy	+50,000	New	+$3.06M	0.2%	63

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Omega Advisors's CLVS Position: Q3 2017 in Review

Omega Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 50,000 shares — an estimated $4.68M sold.

Omega Advisors first reported a position in CLVS in Q2 2017 and held it in 1 quarter. The position peaked at $4.68M in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

Omega Advisors reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
Omega Advisors sold 50,000 Clovis Oncology, Inc. shares in Q3 2017, an estimated $4.68M.
Omega Advisors first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 1 quarter.
Omega Advisors's Clovis Oncology, Inc. position peaked at $4.68M in Q2 2017.
255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Omega Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.